Search
Close this search box.

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics Strategic investors in the merger include Eric Trump, Unusual Machines (NYSE: UMAC), American Ventures, LLC, Protego Ventures, Aliya Capital and Agostinelli Group. Implied acquisition value of $1.5 billion, based on the price

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics Strategic investors in the merger include Eric Trump, Unusual Machines (NYSE: UMAC), American Ventures, LLC, Protego Ventures, Aliya Capital and Agostinelli Group. Implied acquisition value of $1.5 billion, based on the price

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics

JFB and XTEND Announce $1.5B Business Combination to Establish a Nasdaq-Listed US Leader in AI-Driven Autonomous Defense Robotics Strategic investors in the merger include Eric Trump, Unusual Machines (NYSE: UMAC), American Ventures, LLC, Protego Ventures, Aliya Capital and Agostinelli Group. Implied acquisition value of $1.5 billion, based on the price

Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served

Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services

Adds to executive focus on early clinical development and deepens medical and scientific partnership with clients DURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both